

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Thursday 28th March 2024. I am pleased to confirm the following.

BREAST CANCER

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available.

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	37
1.2 Alpelisib (Piqray)	2
1.3 Fulvestrant (fulvestrant or Faslodex)	25
1.4 Palbociclib (Ibrance)	9
1.5 Ribociclib (Kisqali)	39

Q2. How many patients received abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available.

Number patients treated
18

Q3. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of October 2023 and end of December 2023? Please provide data for the latest 3-month period, if Oct to Dec 23 is not available.

Treatment intent	Number patients treated
3.1 Curative	18

3.2 Palliative	19
3.3 Not known / stated	0

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available.

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	12
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	0
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	12

PROSTATE CANCER

Q5. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available.

Name of medicine	Number patients treated
5.1 Abiraterone (Zytiga or generic abiraterone)	5
5.2 Apalutamide (Erleada)	14
5.3 Cabazitaxel (Jevtana or generic cabazitaxel)	4
5.4 Darolutamide (Nubeqa)	11
5.5 Enzalutamide (Xtandi)	63

Q6. How many patients were treated with docetaxel specifically for prostate cancer (ICD-10 code = C61) in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available.

Name of medicine	Number patients treated
Docetaxel	20

Q7. How many patients were treated with the following medicine combinations in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available.

Name of medicine	Number patients treated
7.1 Abiraterone (Zytiga or abiraterone) + Androgen Deprivation Therapy	Information not available on cancer EPMA
7.2 Apalutamide (Erleada) + Androgen Deprivation Therapy	Information not available on cancer EPMA
7.3 Darolutamide (Nubeqa) + Docetaxel + ADT	10
7.4 Enzalutamide (Zytiga) + Androgen Deprivation Therapy	Information not available on cancer EPMA

Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuprorelin, triptorelin, degarelix, flutamide

OVARIAN and ENDOMETRIAL CANCERS

Q8. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available.

Name of medicine	Number patients treated
8.1 Dostarlimab (Jemperli)	1
8.2 Niraparib (Zejula)	5
8.3 Rucaparib (Rubraca)	4

Q9. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines as monotherapy or in combination, in the 3 months between the start of October 2023 and end of December 2023?

Name of medicine	Number patients treated
9.1 Olaparib in total	2
9.2 Olaparib monotherapy	2
9.3 Olaparib + bevacizumab in combination	1

9.4 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin

4

Q10. How many patients were treated for endometrial cancer with the following medicines as monotherapy or in combination, in the 3 months between the start of October 2023 and end of December 2023?

Name of medicine	Number patients treated
10.1 Dostarlimab monotherapy	1
10.2 Dostarlimab + platinum-based chemotherapy, or dostarlimab + carboplatin and paclitaxel	0
10.3 Pembrolizumab (Keytruda) in total	0
10.4 Lenvatinib (Lenvima) in total	0
10.5 Pembrolizumab monotherapy	0
10.6 Pembrolizumab + Lenvatinib (Lenvima) in combination	3

Please be advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Freedom of Information Co-ordinator
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.